Cart
sales@molnova.com
Tenatumomab
CAS No. 1412891-40-7
Tenatumomab( —— )
Catalog No. M37169 CAS No. 1412891-40-7
Tenatumomab (ST2146) is a murine anti-tenascin-C monoclonal antibody used in the study of immune system diseases and lymphomas.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 225 | Get Quote |
|
| 5MG | 350 | Get Quote |
|
| 10MG | 524 | Get Quote |
|
| 25MG | 815 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameTenatumomab
-
NoteResearch use only, not for human use.
-
Brief DescriptionTenatumomab (ST2146) is a murine anti-tenascin-C monoclonal antibody used in the study of immune system diseases and lymphomas.
-
DescriptionTenatumomab (ST2146) is a murine monoclonal antibody against tenascin-C. And tenascin-C, the large extracellular glycoprotein, is overexpressed in cancer. Tenatumomab has been used for Pretargeted Antibody Guided Radioimmunoresearch (PAGRIT), and delivering radionuclides to tumors via PAGRIT and direct 131Iodine labeling approach.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1412891-40-7
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Giannini G, et al. Synthesis and preliminary in vitro evaluation of DOTA-Tenatumomab conjugates for theranostic applications in tenascin expressing tumors. Bioorg Med Chem. 2019 Aug 1;27(15):3248-3253. ?
molnova catalog
related products
-
FLAG peptide
FLAG peptide is an eight amino acids peptide (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys) with an enterokinase-cleavage site used for the purification of recombinant proteins.
-
GLP-1 (7-36) amide (...
GLP-1 (7-36) amide (chicken, common turkey)
-
BMS-P5 free base
BMS-P5 free base is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor.?BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma.
